(Q35015611)

5 August 2017

1 reference

title

Emerging role of pemetrexed in ovarian cancer (English)

1 reference

5 August 2017

1 reference

Federica Tomao

1

1 reference

ORCID Public Data File 2021

author name string

Pierluigi Benedetti Panici

series ordinal

2

1 reference

5 August 2017

Luigi Frati

series ordinal

3

1 reference

5 August 2017

Silverio Tomao

series ordinal

4

1 reference

5 August 2017

publication date

1 December 2009

1 reference

Expert Review of Anticancer Therapy

5 August 2017

published in

1 reference

5 August 2017

volume

9

1 reference

5 August 2017

issue

12

1 reference

5 August 2017

page(s)

1727-1735

1 reference

5 August 2017

cites work

Cancer statistics, 2007

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.141

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.141

Relapsed ovarian cancer: challenges and management strategies for a chronic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.141

Systemic therapy for ovarian cancer: current status and new treatments

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.141

Current concepts of treatment strategies in advanced or recurrent ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.141

Management of recurrent ovarian carcinoma: current status and future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.141

The current treatment of recurrent ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.141

Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.141

Nonplatinum topotecan combinations versus topotecan alone for recurrent ovarian cancer: results of a phase III study of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.141

Topotecan versus treosulfan, an alkylating agent, in patients with epithelial ovarian cancer and relapse within 12 months following 1st-line platinum/paclitaxel chemotherapy. A prospectively randomized phase III trial by the Arbeitsgemeinschaft Gyna

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.141

Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.141

Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.141

Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.141

Oxaliplatin or paclitaxel in patients with platinum-pretreated advanced ovarian cancer: A randomized phase II study of the European Organization for Research and Treatment of Cancer Gynecology Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.141

Long-term survival in a phase III, randomised study of topotecan versus paclitaxel in advanced epithelial ovarian carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.141

Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.141

Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.141

Phase II trial of vinorelbine for relapsed ovarian cancer: a Southwest Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.141

A Phase II study of trabectedin single agent in patients with recurrent ovarian cancer previously treated with platinum-based regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.141

Trabectedin for women with ovarian carcinoma after treatment with platinum and taxanes fails.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.141

A phase I/II study of topotecan in combination with carboplatin in recurrent epithelial ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.141

Combination therapy with gemcitabine and carboplatin in recurrent ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.141

Pemetrexed (ALIMTA), a novel multitargeted antineoplastic agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.141

Front-line treatment of advanced non-small-cell lung cancer with MTA (LY231514, pemetrexed disodium, ALIMTA) and cisplatin: a multicenter phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.141

Phase II study of pemetrexed disodium, a multitargeted antifolate, and cisplatin as first-line therapy in patients with advanced nonsmall cell lung carcinoma: a study of the National Cancer Institute of Canada Clinical Trials Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.141

Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.141

Pemetrexed in bladder, head and neck, and cervical cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.141

A phase II study of pemetrexed and carboplatin in patients with locally advanced or metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.141

The ALPI Trial: the Italian/European experience with adjuvant chemotherapy in resectable non-small lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.141

Pemetrexed (Alimta, LY231514) demonstrates clinical activity in chemonaive patients with cervical cancer in a phase II single-agent trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.141

Evaluation of pemetrexed (Alimta, LY231514) as second line chemotherapy in persistent or recurrent carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.141

Phase II evaluation of pemetrexed in the treatment of recurrent or persistent platinum-resistant ovarian or primary peritoneal carcinoma: a study of the Gynecologic Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.141

A randomised, double-blind, phase II study of two doses of pemetrexed in the treatment of platinum-resistant, epithelial ovarian or primary peritoneal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.141

Management of platinum-resistant ovarian cancer with the combination of pemetrexed and gemcitabine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.141

Phase II study of carboplatin and pemetrexed for the treatment of platinum-sensitive recurrent ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.141

Multitargeted antifolate LY231514 as first-line chemotherapy for patients with advanced non-small-cell lung cancer: A phase II study. National Cancer Institute of Canada Clinical Trials Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.141

Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.141

A phase I evaluation of multitargeted antifolate (MTA, LY231514), administered every 21 days, utilizing the modified continual reassessment method for dose escalation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.141

Two drug interaction studies evaluating the pharmacokinetics and toxicity of pemetrexed when coadministered with aspirin or Ibuprofen in patients with advanced cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.141

Pharmacogenomic strategies provide a rational approach to the treatment of cisplatin-resistant patients with advanced cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.141

Phase II study of gemcitabine (2',2'-difluorodeoxycytidine) in previously treated ovarian cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.141

Synergistic cytotoxicity and pharmacogenetics of gemcitabine and pemetrexed combination in pancreatic cancer cell lines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.141

Preclinical cellular pharmacology of LY231514 (MTA): a comparison with methotrexate, LY309887 and raltitrexed for their effects on intracellular folate and nucleoside triphosphate pools in CCRF-CEM cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.141

Randomized phase II trial of three schedules of pemetrexed and gemcitabine as front-line therapy for advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.141

Vascular endothelial growth factor expression in early stage ovarian carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.141

Bevacizumab and weekly taxane chemotherapy demonstrates activity in refractory ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.141

Salvage bevacizumab (rhuMAB VEGF)-based therapy after multiple prior cytotoxic regimens in advanced refractory epithelial ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.141

Bevacizumab combination therapy in recurrent, platinum-refractory, epithelial ovarian carcinoma: A retrospective analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.141

Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.141

Phase II study of pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.141

Activity of Gemcitabine in Patients with Advanced Ovarian Cancer: Responses Seen Following Platinum and Paclitaxel

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.141

21 January 2018

Identifiers

DOI

10.1586/ERA.09.141

1 reference

5 August 2017

1 reference